title: [Esophageal carcinosarcoma treated with surgery and chemoradiotherapy-a report of 4 cases].
abstract: Esophageal carcinosarcoma is a rare malignant tumor. We report the cases of 4 patients treated with resection and chemoradiotherapy. All patients were men (mean age, 61 years) and presented with dysphagia. Endoscopic examination revealed type 1 tumors in all patients. We planned esophagectomy with extended lymphadenectomy for all patients; however, non-curative resection was performed in 1 patient with extended lymph node metastasis. Curative resection was performed in 3 patients, all of whom showed pT1 wall invasion, and 2 had lymph node metastasis; hence, 1 case was classified as stage I and 2 as stage II. Local recurrence developed in 1 patient at 13 months after curative resection. This patient was treated with chemoradiotherapy and showed a clinical complete response. The patient remains alive without recurrence. The other 2 patients showed no recurrence. Therefore, 3 patients who underwent curative resection survived for more than 5 years. The other patient who underwent non-curative resection died of multiple organ metastasis 111 days after surgery. Because protuberant esophageal carcinosarcoma causes symptoms such as dysphagia, this disease can be diagnosed earlier than esophageal cancer; however, lymph node metastasis at diagnosis is frequently encountered. Surgery with extended lymphadenectomy for esophageal carcinosarcoma results in better prognosis, and chemoradiotherapy is as effective for recurrence as for esophageal cancer.
authors.affiliation: Division of Digestive Surgery, Dept. of Surgery, Kyoto Prefectural University of Medicine.
authors.forename: Kenichi
authors.initials: K
authors.lastname: Takemoto
authors.forename: Atsushi
authors.initials: A
authors.lastname: Shiozaki
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Fujiwara
authors.forename: Hiroki
authors.initials: H
authors.lastname: Shimizu
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Konishi
authors.forename: Shuhei
authors.initials: S
authors.lastname: Komatsu
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kubota
authors.forename: Daisuke
authors.initials: D
authors.lastname: Ichikawa
authors.forename: Kazuma
authors.initials: K
authors.lastname: Okamoto
authors.forename: Ryo
authors.initials: R
authors.lastname: Morimura
authors.forename: Yasutoshi
authors.initials: Y
authors.lastname: Murayama
authors.forename: Hisashi
authors.initials: H
authors.lastname: Ikoma
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Kuriu
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Nakanishi
authors.forename: Chouhei
authors.initials: C
authors.lastname: Sakakura
authors.forename: Eigo
authors.initials: E
authors.lastname: Otsuji
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002296:Carcinosarcoma / Q000628:therapy*; D059248:Chemoradiotherapy; D002945:Cisplatin / Q000008:administration & dosage; D004938:Esophageal Neoplasms / Q000473:pathology / Q000628:therapy*; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging
chemical_list: D002945:Cisplatin; D005472:Fluorouracil